Paper Details

  1. Home
  2. Paper Details

Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers.

Author: CastlesMark A, CongXiuyu Julie, KraftMichael-Friedrich, MacGregorThomas R, MaussStefan, SaboJohn P, WallaceLacey

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study assessed the pharmacokinetics of acyclovir when administered with tipranavir/ritonavir. There were no clinically significant changes in acyclovir pharmacokinetics, suggesting that valacyclovir can be safely co-administered with tipranavir/ritonavir without dose adjustments.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: This study assessed the single-dose pharmacokinetics of the herpes antiviral acyclovir (administered as the pro-drug valacyclovir) alone and in combination with twice-daily 200 mg ritonavir-boosted tipranavir (500 mg) at steady state. METHODS: The study was an open label, one-sequence cr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00228-010-0907-1

データ提供：米国国立医学図書館（NLM）

A Smooth Journey: Tipranavir/Ritonavir and Valacyclovir

This research investigates the potential drug interactions between tipranavir/ritonavir, a combination used to treat HIV, and valacyclovir, an antiviral medication used for herpes infections. This is like navigating a busy caravan route, ensuring that different types of camels can travel together safely and efficiently.

A Safe Passage: No Significant Drug Interaction

The study found no clinically significant interaction between tipranavir/ritonavir and valacyclovir, suggesting that these drugs can be safely co-administered. This is like finding a wide and well-maintained path that allows different types of caravans to travel together without obstruction.

A Clear Path: Navigating Drug Interactions Safely

This research provides valuable information for clinicians who prescribe these medications, assuring safe and effective treatment regimens for patients. It's a reminder that navigating the complex landscape of drug interactions requires careful consideration and research, ensuring a smooth and safe journey for all involved.

Dr. Camel's Conclusion

This research offers reassurance regarding the safety of co-administering tipranavir/ritonavir and valacyclovir, providing a clear path for clinicians to prescribe these medications effectively. It's a testament to the importance of meticulous research in navigating the intricate world of drug interactions, ensuring safe and effective treatment for patients.
Date :
  1. Date Completed 2011-06-15
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

20963404

DOI: Digital Object Identifier

10.1007/s00228-010-0907-1

Related Literature

Article Analysis
・Effects of tipranavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.